Clinical trials
Relapsed Ovarian Cancer clinical trials
Below are recruiting relapsed ovarian cancer clinical trials, each written for real people, not researchers. We’re tracking 69 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT04710797Recruiting
Lymph node surgery for early-stage ovarian cancer
This trial studies whether removing (dissecting) lymph nodes during surgery can improve care for people with early-stage ovarian cancer that still needs chemotherapy. You may be eligible if you have certain ovarian cancer types and your scans and surgery do not show clearly suspicious lymph nodes.
Guangzhou, GuangdongAges 18–70 - NCT03787056Recruiting
Blood test marker study in many cancer types
This study measures a blood marker called progastrin (at diagnosis and during treatment) to see how well it predicts response or outcomes. It may help doctors choose or monitor treatment more precisely for several cancer types.
BronAges 18 years+ - NCT05607329Recruiting
Surgery plus chemo versus chemo alone for ovarian cancer relapse
This trial tests whether doing additional surgery to remove visible tumor (“secondary cytoreduction”) before chemotherapy helps compared with chemotherapy alone. It’s for ovarian (or related) cancer that came back after prior PARP inhibitor maintenance and platinum chemotherapy.
Hangzhou, ZhejiangAges 18–70 - NCT05255471RecruitingPhase 3
Olaparib after surgery for recurrent ovarian cancer
This trial tests whether olaparib (a pill cancer medicine) works better than standard platinum chemotherapy after a second surgery for recurrent ovarian cancer. It’s for people whose cancer returned after initial PARP-inhibitor (PARPi) maintenance and aims to see if treatment can control the cancer for longer with acceptable side effects.
NaplesAges 18 years+ - NCT06028724Recruiting
Looking for cancer mutations using a blood test
This study uses a blood test (liquid biopsy) to find genetic changes in advanced solid tumors. It may help doctors choose the right treatment and monitor how well it works over time.
Aviano, PordononeAges 18 years+ - NCT05446545Recruiting
Blood and tissue tests to monitor ovarian cancer using tumor DNA
This study uses a custom lab test on blood (and tumor tissue) to track ovarian cancer returning and to see how well treatment is working. It may help your care team monitor changes over time, especially after certain surgeries.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT05983276RecruitingPhase 2
Combination therapy for drug-resistant ovarian cancer
This trial tests a new two-drug combination (decitabine and selinexor) given with standard chemotherapy to see if it can reverse drug resistance in ovarian cancer that has come back or worsened after treatment.
Maywood, IllinoisAges 18 years+ - NCT06307249RecruitingPhase 1
Precision therapy for solid tumors targeting CDK4/6 and VEGF
This trial tests a combination of two targeted drugs for advanced solid tumors like colorectal, lung, breast, and genitourinary cancers. The goal is to see if blocking certain proteins and a long RNA molecule can slow tumor growth.
Tripoli, North LebanonAges 18 years+ - NCT05080556RecruitingPhase 2
Adaptive chemotherapy for ovarian cancer after platinum and PARP
This trial tests a personalized (adaptive) chemotherapy plan for people with certain types of ovarian/fallopian tube/peritoneal cancer who already had platinum chemotherapy and a PARP inhibitor. It’s for patients whose cancer came back after (or still responds to) prior platinum treatment and may help delay disease progression.
LondonAges 18 years+ - NCT04921527RecruitingPhase 3
Chiauranib with weekly paclitaxel for tough ovarian cancer
This Phase 3 trial tests whether chiauranib combined with weekly paclitaxel can shrink recurrent ovarian, fallopian tube, or primary peritoneal cancer that did not respond to platinum chemotherapy. It is designed for people who have limited treatment options after platinum-resistant or platinum-refractory disease.
Shanghai, ChinaAges 18–70 - NCT06735326RecruitingPhase 2
Fluzoparib and Bevacizumab Before Surgery for Advanced Ovarian Cancer
This trial tests whether combining fluzoparib (a PARP inhibitor) with or without bevacizumab (a blood vessel growth blocker) before surgery can shrink advanced ovarian cancer. It is for women with a BRCA gene mutation whose cancer cannot be fully removed with surgery right now.
Jinan, ShandongAges 18 years+ - NCT05200260RecruitingPhase 2
Surgery plus maintenance medicines for advanced ovarian cancer
This trial checks whether having surgery to remove as much tumor as possible, followed by ongoing targeted treatment, helps people with advanced ovarian (and related) cancers live longer and/or control cancer better. It specifically uses tumor-testing results to match patients and then continues treatment after surgery.
FoshanAges 18 years+ - NCT05704621RecruitingPhase 2
Surgery after PARP inhibitor failure in returning ovarian cancer
This trial tests whether doing additional (“secondary”) tumor-removal surgery can help people with ovarian, fallopian tube, or primary peritoneal cancer that has returned after PARP inhibitor maintenance. It focuses on people whose cancer can likely be fully removed and who are considered good candidates for surgery and follow-up treatment.
SeoulAges 18 years+ - NCT07306559RecruitingPhase 1
Testing a new drug for advanced solid tumors
This trial tests different doses of a new drug (BI 3820768) in people with advanced solid tumors, specifically germ cell tumors, endometrial cancer, or ovarian cancer. The goal is to see if the drug is safe and how well it works.
Los Angeles, CaliforniaAges 18 years+ - NCT06791460RecruitingPhase 2/Phase 3
A study of two drug combinations for ovarian cancer that came back
This trial tests a common chemotherapy (Pegylated Liposomal Doxorubicin) plus an immunotherapy (Adebrelimab), with or without a bladder medication (Mirabegron), in people whose ovarian cancer has returned after initial treatment. The goal is to see if adding Mirabegron helps the other drugs work better.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06014528RecruitingPhase 2
IN10018 plus liposomal doxorubicin for platinum-resistant ovarian cancer
This trial tests if adding the drug IN10018 to standard chemotherapy (liposomal doxorubicin) can help women with ovarian cancer that has stopped responding to platinum-based treatments. It aims to see if the combination works better than chemotherapy alone.
BeijingAges 18 years+ - NCT07067255RecruitingPhase 1/Phase 2
Sequential CAR-T cells for advanced ovarian cancer with CD146 and GPC3
This trial tests a new type of immunotherapy called CAR-T cells that are designed to attack ovarian cancer cells that have two specific markers (CD146 and GPC3). It is for people with advanced ovarian cancer who have already tried standard treatments like platinum-based chemotherapy and need new options.
Beijing, Beijing MunicipalityAges 21–90 - NCT07059845RecruitingPhase 2
Studying mirvetuximab combos for ovarian cancer
This trial tests multiple combinations of the drug mirvetuximab soravtansine with other treatments for people with ovarian cancer. It aims to see how well these combos work and what side effects they cause.
La Jolla, CaliforniaAges 18 years+ - NCT06964009RecruitingPhase 1
New drug plus paclitaxel for resistant ovarian cancer
This trial tests a new drug called DT2216 combined with the chemotherapy drug paclitaxel for ovarian cancer that has stopped responding to platinum-based chemo. The goal is to see if this combination can shrink or slow the cancer, and to find a safe dose.
Boston, MassachusettsAges 18 years+ - NCT06930755RecruitingPhase 1
Study of an oral drug for recurrent ovarian cancer
This study tests a new oral drug called NMS-03305293 for women with recurrent ovarian cancer. It may work by targeting a specific protein involved in cancer growth. You may be eligible if you have high-grade serous ovarian cancer, have had limited prior treatments, and do not have a BRCA mutation.
Peoria, IllinoisAges 18 years+ - NCT06799065RecruitingPhase 1/Phase 2
Oral drug for advanced solid tumors including ovarian cancer
This trial tests a new daily pill that targets a protein helping cancer cells divide. It may stop tumors from growing in people with advanced or metastatic cancer that has returned or stopped responding to standard treatments, including some types of ovarian, lung, and other solid tumors.
Aurora, ColoradoAges 18 years+ - NCT06639074RecruitingPhase 2
Folate receptor dendritic cell vaccine for ovarian cancer
This trial tests a personalized vaccine made from your own immune cells, designed to target a protein called folate receptor alpha found on many ovarian cancer cells. It is for people who have finished initial chemotherapy and have no signs of cancer remaining, to try to prevent it from coming back.
Scottsdale, ArizonaAges 18 years+ - NCT06366490RecruitingPhase 1
Personalized vaccine for recurrent ovarian cancer
This trial tests a personalized cancer vaccine made from your own tumor cells. It is for women with advanced ovarian, fallopian tube, or primary peritoneal cancer that has returned after at least one round of platinum chemotherapy.
Duarte, CaliforniaAges 18 years+ - NCT05236686Recruiting
Surgery to remove upper abdomen lymph nodes for ovarian cancer
This trial studies whether removing lymph nodes in the upper abdomen (hepatoceliac lymph nodes) improves outcomes for people with stage III or IV ovarian, fallopian tube, or primary peritoneal cancer that has spread to those lymph nodes. It also looks at how this surgery works for people with certain types of relapse, often alongside chemotherapy.
ShanghaiAges 18–75
Hear when a new Relapsed Ovarian Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for relapsed ovarian cancer?
- Yes. Clin2 currently lists 69 recruiting relapsed ovarian cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a relapsed ovarian cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a relapsed ovarian cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.